Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Public ClinicalTrials.gov record NCT02421588. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer (CORAIL Trial)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).
Study identification
- NCT ID
- NCT02421588
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 442 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2015 (Type not available)
- Primary completion
- Oct 12, 2018 (Actual)
- Completion
- Oct 12, 2018 (Actual)
- Last update posted
- Apr 3, 2020
2015 – 2018
United States locations
- U.S. sites
- 28
- U.S. states
- 15
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1112 | Peoria | Arizona | — | — |
| 1102 | Greenbrae | California | — | — |
| 1103 | La Jolla | California | — | — |
| 1116 | Los Angeles | California | — | — |
| 1120 | Los Angeles | California | — | — |
| 1113 | Palo Alto | California | — | — |
| 1111 | San Francisco | California | — | — |
| 1122 | Santa Maria | California | — | — |
| 1123 | West Hills | California | — | — |
| 1109 | Augusta | Georgia | — | — |
| 1104 | Indianapolis | Indiana | — | — |
| 1110 | Covington | Louisiana | — | — |
| 1124 | Scarborough | Maine | — | — |
| 1121 | Brick | New Jersey | — | — |
| 1127 | Albany | New York | — | — |
| 1105 | New York | New York | — | — |
| 1117 | Asheville | North Carolina | — | — |
| 1101 | Charlotte | North Carolina | — | — |
| 1125 | Charlotte | North Carolina | — | — |
| 1108 | Durham | North Carolina | — | — |
| 1107 | Columbus | Ohio | — | — |
| 1118 | Dayton | Ohio | — | — |
| 1119 | Pittsburgh | Pennsylvania | — | — |
| 1115 | Greenville | South Carolina | — | — |
| 1129 | Nashville | Tennessee | — | — |
| 1131 | Fort Worth | Texas | — | — |
| 1128 | Houston | Texas | — | — |
| 1106 | Charlottesville | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02421588, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 3, 2020 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02421588 live on ClinicalTrials.gov.